Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 4, 2026, 1:56 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 817–835 of 835 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Placebo SC Injection Clear all

Conditions: Chronic Obstructive Pulmonary Disease (COPD)
Interventions: Tezepelumab, Placebo; Biological · Other
Lead sponsor: AstraZeneca; Industry
Eligibility: 40 Years to 80 Years
Enrollment: 990 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 80
States / cities: Birmingham, Alabama • Cullman, Alabama • Phoenix, Arizona + 73 more

Conditions: Giant Cell Arteritis
Interventions: Sarilumab SAR153191, Sarilumab matching placebo, Prednisone, Prednisone matching placebo; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 50 Years and older
Enrollment: 83 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 6
States / cities: Boca Raton, Florida • Gainesville, Florida • Iowa City, Iowa + 3 more

Conditions: Diabetes Mellitus, Non-Insulin-Dependent
Interventions: INGAP-Peptide, placebo; Drug
Lead sponsor: Exsulin Corporation; Industry
Eligibility: 35 Years to 70 Years
Enrollment: 126 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2004
U.S. locations: 17
States / cities: La Jolla, California • San Diego, California • Walnut Creek, California + 13 more

Conditions: Infant, Newborn
Interventions: Darbepoetin Alfa Injection, erythropoietin alfa injection, sham injection; Drug
Lead sponsor: University of New Mexico; Other
Eligibility: 1 Hour to 49 Hours
Enrollment: 102 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2014
U.S. locations: 3
States / cities: Denver, Colorado • Ogden, Utah • Salt Lake City, Utah

Conditions: Healthy Subjects
Interventions: 1.25 mg/kg BL-8040 + BL-8040-matching placebo, 2 mg/kg BL-8040, BL-8040-matching placebo, 400 mg Moxifloxacin (1x400 mg tablet); Drug
Lead sponsor: BioLineRx, Ltd.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 38 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Phoenix, Arizona

Conditions: Diabetes Mellitus, Type 2
Interventions: AMG 127, Placebo; Drug
Lead sponsor: Amgen; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 162 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2027
U.S. locations: 2
States / cities: Lake Forest, California • Aventura, Florida

Conditions: Osteoporosis, Postmenopausal
Interventions: Blosozumab, Placebo; Biological · Other
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 45 Years and older · Female only
Enrollment: 28 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015
U.S. locations: 3
States / cities: Daytona Beach, Florida • Evansville, Indiana • Dallas, Texas

Conditions: Atherosclerotic Cardiovascular Disease
Interventions: Inclisiran, Placebo; Drug
Lead sponsor: University of Oxford; Other
Eligibility: 40 Years and older
Enrollment: 16,124 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2049
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Type 2 Diabetes Mellitus
Interventions: Exenatide SC, Exenatide IV, Placebo SC, Exendin-9, Placebo IV; Drug
Lead sponsor: Carl T. Hayden VA Medical Center; Federal
Eligibility: 35 Years to 70 Years
Enrollment: 76 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 1
States / cities: Phoenix, Arizona

Conditions: Atopic Dermatitis
Interventions: Tralokinumab, Placebo; Drug
Lead sponsor: LEO Pharma; Industry
Eligibility: 18 Years and older
Enrollment: 380 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 21
States / cities: Birmingham, Alabama • Encinitas, California • Fountain Valley, California + 17 more

Conditions: Prurigo Nodularis
Interventions: Nemolizumab 30 mg, Placebo; Drug
Lead sponsor: Galderma R&D; Industry
Eligibility: 18 Years and older
Enrollment: 286 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 38
States / cities: Birmingham, Alabama • Los Angeles, California • Sacramento, California + 32 more

Conditions: Chronic Spontaneous Urticaria
Interventions: Dupilumab SAR231893, Placebo, non sedating H1-antihistamine; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 6 Years to 80 Years
Enrollment: 397 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2024
U.S. locations: 16
States / cities: Los Angeles, California • Sarasota, Florida • Sweetwater, Florida + 13 more

Conditions: Pulmonary Hypertension, Heart Failure With Preserved Ejection Fraction
Interventions: TX000045- Dose A, TX000045- Dose B, Placebo; Drug
Lead sponsor: Tectonic Therapeutic; Industry
Eligibility: 18 Years to 83 Years
Enrollment: 191 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 25
States / cities: Phoenix, Arizona • Scottsdale, Arizona • San Francisco, California + 21 more

Conditions: Asthma
Interventions: dupilumab, Matching placebo; Drug
Lead sponsor: Regeneron Pharmaceuticals; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 13
States / cities: Rolling Hills Estates, California • Torrance, California • Westminster, California + 10 more

Conditions: Safety, Pharmacokinetics, Healthy Subjects
Interventions: Anifrolumab SC injection (300mg), Anifrolumab IV infusion (300mg), Anifrolumab SC infusion (600mg), Anifrolumab placebo SC injection (300mg), Anifrolumab placebo IV infusion (300mg), Anifrolumab placebo SC infusion (600mg); Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Obesity, Overweight
Interventions: LY3437943, Placebo; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 338 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 25
States / cities: Scottsdale, Arizona • Anaheim, California • Fresno, California + 21 more

Conditions: Spinal Muscular Atrophy (SMA)
Interventions: RO7204239, Placebo, Risdiplam; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 2 Years to 25 Years
Enrollment: 97 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 2
States / cities: Boston, Massachusetts • New York, New York

Conditions: Obesity, Overweight, Overweight With One Weight Related Comorbidity
Interventions: RO7204239, RO7204239 Matching Placebo, Tirzepatide; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 285 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 19
States / cities: Anniston, Alabama • Spring Valley, California • Clermont, Florida + 16 more

Conditions: Chronic Rhinosinusitis Without Nasal Polyps
Interventions: Itepekimab (SAR440340), Placebo, Mometasone furoate nasal spray (MFNS); Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years and older
Enrollment: 66 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 10
States / cities: Birmingham, Alabama • La Jolla, California • Murrieta, California + 7 more

Search by objective public record fields.

A Study to Investigate the Efficacy and Safety of Tezepelumab in Adult Participants With Moderate to Very Severe COPD (D5241C00007)

Evaluation of Efficacy and Safety of Sarilumab in Patients With GCA

Safety and Efficacy of INGAP-Peptide in Patients With Type 2 Diabetes

Darbepoetin Administration to Preterm Infants

Study to Investigate the Effect of BL-8040 (Motixafortide) on the QTc Interval in Healthy Subjects

A Trial Evaluating AMG 127 in Healthy Participants and Participants With Type 2 Diabetes Mellitus

A Study of 2 Different Formulations of Blosozumab (LY2541546) in Post Menopausal Women

A Randomized Trial Assessing the Effects of Inclisiran on Clinical Outcomes Among People With Cardiovascular Disease

The Study of Exenatide Action on Vessel Function in Type 2 Diabetes and Prediabetes

Tralokinumab in Combination With Topical Corticosteroids for Moderate to Severe Atopic Dermatitis - ECZTRA 3

Study to Assess the Efficacy and Safety of Nemolizumab (CD14152) in Participants With Prurigo Nodularis (PN)

Dupilumab for the Treatment of Chronic Spontaneous Urticaria in Patients Who Remain Symptomatic Despite the Use of H1 Antihistamine and Who Are naïve to, Intolerant of, or Incomplete Responders to Omalizumab (LIBERTY-CSU CUPID)

A Study of TX000045 in Patients With Pulmonary Hypertension Secondary to Heart Failure With Preserved Ejection Fraction (the APEX Study)

A Study to Evaluate the Effect of Dupilumab on Exercise Capacity in Adult Patients With Asthma

A Study to Assess the Pharmacokinetics and Safety of Single Doses of Anifrolumab in Healthy Subjects

A Study of LY3437943 in Participants Who Have Obesity or Are Overweight

A Study to Investigate the Safety and Efficacy of RO7204239 in Combination With Risdiplam (RO7034067) in Participants With Spinal Muscular Atrophy

A Study to Assess Efficacy, Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of RO7204239 in Combination With Tirzepatide in Participants With Obesity or Overweight With At Least One Weight-related Comorbidity

A Proof-of-Concept Study to Assess the Efficacy, Safety and Tolerability of Itepekimab (Anti--IL-33 mAb) in Participants With Chronic Rhinosinusitis Without Nasal Polyps